In reply: We thank Dr. Sokbom Kang for his interest in our investigation and his kind remarks. Obviously patients selected for neoadjuvant chemotherapy (NAC) are a selected unfavorable group of ovarian cancer patients. The advantage of this approach as we have mentioned in our paper include an increased rate of optimal residual disease, less extensive surgery, reduced blood loss, lower morbidity, shortened hospital stay and improved quality of life. In spite of these advantages, NAC has not been shown to be superior with regard to outcome over up front surgery. It has only been shown not to be inferior to up front surgery [1] . The high rate of optimal cytoreduction in the total group (<0.5 cm in 86.5%) precluded a meaningful comparison between the rate of successful cytoreduction between good and poor responders, in our limited number of patients. Indeed as the Dr. Sokbom Kang noted "all patients may be similarly benefited by NAC in terms of surgical respectability".
